Caldolor® Demonstrates Favorable Safety Profile In Newborns

  • Published Month : Tuesday, 17 Mar 2020 08:00 pm

Caldolor® (ibuprofen) Injection studied in infants from birth to 6 months old

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced topline results from a clinical study evaluating the safety and pharmacokinetics of Caldolor® (ibuprofen) Injection in children ranging from birth to six months of age. Topline results from this study indicate that Caldolor was well tolerated overall in this patient population, with no safety concerns noted.

The open-label trial enrolled 24 newborns at four medical centers across the country. The study data  indicated that the pharmacokinetics of Caldolor behaves similarly between these very young children and those greater than 6 months of age. Next steps include finalizing the full study report for submission to the FDA and then determining whether an additional pediatric indication will be available.

"We remain committed to the ongoing development of our brands, and are working to make them available to new patient populations," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals.

At the time of Caldolor's New Drug Application (NDA) approval, the FDA requested a series of Phase IV studies to evaluate the product in pediatric patients. Cumberland had previously completed a pain and a fever study leading to an expanded Caldolor label - with FDA approval - for use in children 6 months and older. Cumberland completed the last of these requirements through this clinical study of the use of Caldolor in the youngest of patients.

About The Insight Partners:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

A PHP Error was encountered

Severity: Warning

Message: count(): Parameter must be an array or an object that implements Countable

Filename: amp/news_details_amp.php

Line Number: 252

Backtrace:

File: /home/smartmarketnews/public_html/application/views/amp/news_details_amp.php
Line: 252
Function: _error_handler

File: /home/smartmarketnews/public_html/application/controllers/Amp_controller.php
Line: 41
Function: view

File: /home/smartmarketnews/public_html/index.php
Line: 315
Function: require_once

Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

media@smartmarketnews.com | sales@smartmarketnews.com

Contact Us
Visit Our Sites
© The News and Media Division of The Insight Partners 2019 | All Rights Reserved | Privacy Policy